Fig. 4From: Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trialsIndividual patient baseline PiB-PET SUVr values (all PiB-PET population). ApoE, apolipoprotein E; PiB-PET, 11C-Pittsburgh compound B positron emission tomography; SUVr, standardized uptake value ratioBack to article page